Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...

Add Yahoo as a preferred source to see more of our stories on Google. The FDA has approved LIB Therapeutics’ Lerochol (lerodalcibep-liga), a once-monthly, subcutaneously administered proprotein ...

The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...

The FDA approved lerodalcibep (Lerochol) injections for the treatment of elevated LDL cholesterol in adults, maker LIB Therapeutics announced. A third-generation PCSK9 inhibitor, lerodalcibep is ...

It cannot be denied that statins have revolutionized how we treat and prevent coronary heart disease. But there are both external and intrinsic reasons why some patients do not respond adequately to ...

Adding a PCSK9 inhibitor to maximally tolerated statins after a coronary or peripheral artery revascularization can help patients achieve LDL cholesterol goals better than standard care, data from the ...

Merck & Co. has completed a hat trick of phase 3 victories for its oral PCSK9 inhibitor. Navigating into the broader hyperlipidemia population, the drugmaker stayed out of the shoals and charted a ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with high ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, lipid-lowering drugs, were associated with a 22% lower risk for nonmelanoma skin cancer (NMSC) in patients with atherosclerotic ...

Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...